文献速递临床免疫分子诊断

快速自动化荧光侧流免疫分析法检测乙肝表面抗原及抗体与丙肝抗体的开发

Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C.
PubMed 文献 · Ann Lab Med · 2018-01-01

本研究开发了一种20分钟内完成定性检测的自动化荧光侧流免疫分析法AFIAS,用于检测HBsAg、抗-HBs和抗-HCV。用20份血清转换盘和3500份临床血清样本与自动化化学发光免疫分析法比较,AFIAS的灵敏度和特异性分别为HBsAg 99.8%和99.3%、抗-HBs 100.0%和100.0%、抗-HCV 98.8%和99.1%,与Elecsys的一致率分别为99.4%、100.0%和99.0%。结论认为AFIAS诊断性能与现有自动化CLIA相当,可用于低资源实验室的大规模筛查。

要点

  • AFIAS可在20分钟内定性检测HBsAg、抗-HBs和抗-HCV。
  • 临床样本中AFIAS三项检测的灵敏度98.8%-100.0%,特异性99.1%-100.0%。
  • AFIAS与Elecsys检测的一致率为99.0%-100.0%。

核心结论

  • AFIAS的HBsAg、抗-HBs和抗-HCV检测诊断性能与当前自动化CLIA相当。
  • AFIAS可用于低资源实验室或中低收入地区的大规模HBV或HCV筛查。

研究设计与样本

  • 开发了基于小型台式荧光读取器的自动化荧光侧流免疫分析法AFIAS,用于定性检测HBsAg、抗-HBs和抗-HCV,检测时间在20分钟内。
  • 使用20份血清转换盘和3500份临床血清样本,将AFIAS与自动化CLIA(Elecsys和ARCHITECT)进行诊断性能比较。

主要发现

  • 血清转换盘评估显示AFIAS对HBsAg和抗-HCV检测具有足够的灵敏度。
  • 临床样本中AFIAS的灵敏度与特异性分别为:HBsAg 99.8%和99.3%,抗-HBs 100.0%和100.0%,抗-HCV 98.8%和99.1%。
  • AFIAS与Elecsys HBsAg、抗-HBs和抗-HCV检测的一致率分别为99.4%、100.0%和99.0%。
  • AFIAS检测出所有HBsAg基因型A-F和H以及抗-HCV基因型1、1a、1b、2a、2b、4和6的样本。
  • 未观察到与其他感染的交叉反应。

临床怎么用

  • 在无法负担自动化化学发光免疫分析仪的实验室中,可考虑使用AFIAS进行HBV和HCV感染筛查。
  • AFIAS适用于低资源实验室或中低收入地区的大规模HBV或HCV筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate, rapid, and cost-effective screening tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection may be useful in laboratories that cannot afford automated chemiluminescent immunoassays (CLIAs). We evaluated the diagnostic performance of a novel rapid automated fluorescent lateral flow immunoassay (LFIA). METHODS: A fluorescent LFIA using a small bench-top fluorescence reader, Automated Fluorescent Immunoassay System (AFIAS; Boditech Med Inc., Chuncheon, Korea), was developed for qualitative detection of hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HCV (anti-HCV) within 20 minutes. We compared the diagnostic performance of AFIAS with that of automated CLIAs-Elecsys (Roche Diagnostics GmbH, Penzberg, Germany) and ARCHITECT (Abbott Laboratories, Abbott Park, IL, USA)-using 20 seroconversion panels and 3,500 clinical serum samples. RESULTS: Evaluation with the seroconversion panels demonstrated that AFIAS had adequate sensitivity for HBsAg and anti-HCV detection. From the clinical samples, AFIAS sensitivity and specificity were 99.8% and 99.3% for the HBsAg test, 100.0% and 100.0% for the anti-HBs test, and 98.8% and 99.1% for the anti-HCV test, respectively. Its agreement rates with the Elecsys HBsAg, anti-HBs, and anti-HCV detection assays were 99.4%, 100.0%, and 99.0%, respectively. AFIAS detected all samples with HBsAg genotypes A-F and H and anti-HCV genotypes 1, 1a, 1b, 2a, 2b, 4, and 6. Cross-reactivity with other infections was not observed. CONCLUSIONS: The AFIAS HBsAg, anti-HBs, and anti-HCV tests demonstrated diagnostic performance equivalent to current automated CLIAs. AFIAS could be used for a large-scale HBV or HCV screening in low-resource laboratories or low-to middle-income areas.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Ryu JH, Kwon M, Moon JD, et al. Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C. Ann Lab Med. 2018. PMID: 30027702. doi:10.3343/alm.2018.38.6.578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。